Clinical study on the treatment of depression with venlafaxine under the guidance of pharmacogenomics testing
ObjectiveTo investigate the efficacy and safety of venlafaxine in the treatment of depression under the guidance of pharmacogenomics testing， and to provide references for individualized medication.MethodsA total of 66 patients who met the diagnostic criteria of International Classification of Disea...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | zho |
| Published: |
Editorial Office of Sichuan Mental Health
2021-06-01
|
| Series: | Sichuan jingshen weisheng |
| Subjects: | |
| Online Access: | http://www.psychjm.net.cn/scjswszzen/ch/reader/view_abstract.aspx?file_no=202103010&flag=1 |
| _version_ | 1797627580112699392 |
|---|---|
| author | Xu Jinbing Huang Wei Guo Huagui Huang Shiqing Tang Chaohua Liang Jiaquan Li Xuesong |
| author_facet | Xu Jinbing Huang Wei Guo Huagui Huang Shiqing Tang Chaohua Liang Jiaquan Li Xuesong |
| author_sort | Xu Jinbing |
| collection | DOAJ |
| description | ObjectiveTo investigate the efficacy and safety of venlafaxine in the treatment of depression under the guidance of pharmacogenomics testing， and to provide references for individualized medication.MethodsA total of 66 patients who met the diagnostic criteria of International Classification of Diseases， tenth edition （ICD-10） for depressive episode were included in the study. Patients who were recommended to be treated with venlafaxine in the pharmacogenomics testing report were divided into study group （n=32）， and those who were decided to be treated with venlafaxine by doctors after consultation with patients were divided into control group （n=34）. At the baseline and the end of the 2nd， 4th， 6th and 8th weekend of treatment， Hamilton Depression Scale-24 item （HAMD-24） was adopted to evaluate the clinical efficacy. Meanwhile， Sheehan Disability Scale （SDS） was applied to measure the social function of patients at the baseline and the end of the 8th weekend of treatment. After treatment， Treatment Emergent Symptom Scale （TESS） was used to assess the incidence of adverse reactions.ResultsAt the end of the 4th， 6th and 8th weekend of treatment， HAMD-24 scores in the study group were all lower than those in the control group， with statistical differences （t=2.344， 4.316， 5.760， P<0.05 or 0.01）. At the end of the 8th weekend of treatment， SDS score of the study group was lower than that of the control group， with statistical difference （t=2.173， P<0.05）. The adverse reaction rate in the study group was lower than that in the control group， with statistical difference （χ2=5.720， P<0.05）.ConclusionTreatment of depression with venlafaxine based on pharmacogenetic testing is an effective and safe way to alleviate the depression symptoms in patients. |
| first_indexed | 2024-03-11T10:26:21Z |
| format | Article |
| id | doaj.art-11cd8cd0796947878942876802ad59c7 |
| institution | Directory Open Access Journal |
| issn | 1007-3256 |
| language | zho |
| last_indexed | 2024-03-11T10:26:21Z |
| publishDate | 2021-06-01 |
| publisher | Editorial Office of Sichuan Mental Health |
| record_format | Article |
| series | Sichuan jingshen weisheng |
| spelling | doaj.art-11cd8cd0796947878942876802ad59c72023-11-15T12:18:07ZzhoEditorial Office of Sichuan Mental HealthSichuan jingshen weisheng1007-32562021-06-0134323924210.11886/scjsws202101240011007-3256（2021）03-0239-04Clinical study on the treatment of depression with venlafaxine under the guidance of pharmacogenomics testingXu JinbingHuang WeiGuo HuaguiHuang ShiqingTang ChaohuaLiang JiaquanLi XuesongObjectiveTo investigate the efficacy and safety of venlafaxine in the treatment of depression under the guidance of pharmacogenomics testing， and to provide references for individualized medication.MethodsA total of 66 patients who met the diagnostic criteria of International Classification of Diseases， tenth edition （ICD-10） for depressive episode were included in the study. Patients who were recommended to be treated with venlafaxine in the pharmacogenomics testing report were divided into study group （n=32）， and those who were decided to be treated with venlafaxine by doctors after consultation with patients were divided into control group （n=34）. At the baseline and the end of the 2nd， 4th， 6th and 8th weekend of treatment， Hamilton Depression Scale-24 item （HAMD-24） was adopted to evaluate the clinical efficacy. Meanwhile， Sheehan Disability Scale （SDS） was applied to measure the social function of patients at the baseline and the end of the 8th weekend of treatment. After treatment， Treatment Emergent Symptom Scale （TESS） was used to assess the incidence of adverse reactions.ResultsAt the end of the 4th， 6th and 8th weekend of treatment， HAMD-24 scores in the study group were all lower than those in the control group， with statistical differences （t=2.344， 4.316， 5.760， P<0.05 or 0.01）. At the end of the 8th weekend of treatment， SDS score of the study group was lower than that of the control group， with statistical difference （t=2.173， P<0.05）. The adverse reaction rate in the study group was lower than that in the control group， with statistical difference （χ2=5.720， P<0.05）.ConclusionTreatment of depression with venlafaxine based on pharmacogenetic testing is an effective and safe way to alleviate the depression symptoms in patients.http://www.psychjm.net.cn/scjswszzen/ch/reader/view_abstract.aspx?file_no=202103010&flag=1pharmacogenomics testingvenlafaxinedepressionindividualized treatment |
| spellingShingle | Xu Jinbing Huang Wei Guo Huagui Huang Shiqing Tang Chaohua Liang Jiaquan Li Xuesong Clinical study on the treatment of depression with venlafaxine under the guidance of pharmacogenomics testing Sichuan jingshen weisheng pharmacogenomics testing venlafaxine depression individualized treatment |
| title | Clinical study on the treatment of depression with venlafaxine under the guidance of pharmacogenomics testing |
| title_full | Clinical study on the treatment of depression with venlafaxine under the guidance of pharmacogenomics testing |
| title_fullStr | Clinical study on the treatment of depression with venlafaxine under the guidance of pharmacogenomics testing |
| title_full_unstemmed | Clinical study on the treatment of depression with venlafaxine under the guidance of pharmacogenomics testing |
| title_short | Clinical study on the treatment of depression with venlafaxine under the guidance of pharmacogenomics testing |
| title_sort | clinical study on the treatment of depression with venlafaxine under the guidance of pharmacogenomics testing |
| topic | pharmacogenomics testing venlafaxine depression individualized treatment |
| url | http://www.psychjm.net.cn/scjswszzen/ch/reader/view_abstract.aspx?file_no=202103010&flag=1 |
| work_keys_str_mv | AT xujinbing clinicalstudyonthetreatmentofdepressionwithvenlafaxineundertheguidanceofpharmacogenomicstesting AT huangwei clinicalstudyonthetreatmentofdepressionwithvenlafaxineundertheguidanceofpharmacogenomicstesting AT guohuagui clinicalstudyonthetreatmentofdepressionwithvenlafaxineundertheguidanceofpharmacogenomicstesting AT huangshiqing clinicalstudyonthetreatmentofdepressionwithvenlafaxineundertheguidanceofpharmacogenomicstesting AT tangchaohua clinicalstudyonthetreatmentofdepressionwithvenlafaxineundertheguidanceofpharmacogenomicstesting AT liangjiaquan clinicalstudyonthetreatmentofdepressionwithvenlafaxineundertheguidanceofpharmacogenomicstesting AT lixuesong clinicalstudyonthetreatmentofdepressionwithvenlafaxineundertheguidanceofpharmacogenomicstesting |